- Home
- EWTX
as 07-26-2024 4:00pm EST
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | BOULDER |
| Market Cap: | 2.1B | IPO Year: | 2021 |
| Target Price: | $33.20 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.55 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.12 - $23.50 | Next Earning Date: | 08-08-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Edgewise Therapeutics Inc. (EWTX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Donovan Joanne M. | EWTX | CMO | May 1 '24 | Sell | $18.91 | 3,682 | $69,626.62 | 19,897 | SEC Form 4 |
| KOCH KEVIN | EWTX | President and CEO | May 1 '24 | Sell | $18.91 | 3,152 | $59,604.32 | 14,478 | SEC Form 4 |
| Carruthers R Michael | EWTX | Chief Financial Officer | May 1 '24 | Sell | $18.91 | 2,157 | $40,788.87 | 35,230 | SEC Form 4 |
| Derakhshan Behrad | EWTX | Chief Business Officer | May 1 '24 | Sell | $18.91 | 1,718 | $32,487.38 | 13,422 | SEC Form 4 |
| MOORE JOHN R | EWTX | General Counsel | May 1 '24 | Sell | $18.91 | 1,956 | $36,987.96 | 3,252 | SEC Form 4 |
| Russell Alan J | EWTX | Chief Scientific Officer | May 1 '24 | Sell | $18.91 | 1,576 | $29,802.16 | 7,238 | SEC Form 4 |
| Derakhshan Behrad | EWTX | Chief Business Officer | Feb 7 '24 | Sell | $20.04 | 4,800 | $96,209.28 | 7,020 | SEC Form 4 |
| Derakhshan Behrad | EWTX | Chief Business Officer | Feb 7 '24 | Sell | $20.01 | 4,600 | $92,048.76 | 7,020 | SEC Form 4 |
| Derakhshan Behrad | EWTX | Chief Business Officer | Feb 7 '24 | Sell | $20.00 | 600 | $12,000.00 | 7,020 | SEC Form 4 |
| Carruthers R Michael | EWTX | Chief Financial Officer | Jan 23 '24 | Sell | $15.78 | 90,000 | $1,419,759.00 | 29,024 | SEC Form 4 |
| Thompson Peter A. | EWTX | Director10% Owner | Jan 23 '24 | Buy | $11.00 | 454,545 | $4,999,995.00 | 14,436,497 | SEC Form 4 |
| ORBIMED ADVISORS LLC | EWTX | Director10% Owner | Jan 23 '24 | Buy | $11.00 | 454,545 | $4,999,995.00 | 14,436,497 | SEC Form 4 |
| Fox Jonathan C | EWTX | Director | Dec 26 '23 | Buy | $9.30 | 10,857 | $100,958.16 | 10,857 | SEC Form 4 |
| Russell Alan J | EWTX | Chief Scientific Officer | Dec 26 '23 | Sell | $9.33 | 172,585 | $1,610,097.24 | 3,606 | SEC Form 4 |
Latest Edgewise Therapeutics Inc. News
EWTX Breaking Stock News: Dive into EWTX Ticker-Specific Updates for Smart Investing
TipRanks
5 days ago
‘Don’t Be Scared of Heights’: J.P. Morgan Suggests 2 Stocks to Buy
Zacks
9 days ago
Here's Why Edgewise Therapeutics, Inc. (EWTX) is a Great Momentum Stock to Buy
Investor's Business Daily
10 days ago
Three Surprising Names That Could Be On Biogen's Buyout Shortlist
MT Newswires
17 days ago
Top Midday Gainers
MT Newswires
17 days ago
JPMorgan Raises Price Target on Edgewise Therapeutics to $30 From $27, Maintains Overweight Rating
GuruFocus.com
3 months ago
Edgewise Therapeutics Inc (EWTX) Reports First Quarter 2024 Financial Results
Business Wire
3 months ago
Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024
MT Newswires
3 months ago
Wedbush Raises Edgewise Therapeutics' PT to $31 From $26, Keeps Outperform Rating
Compare EWTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "EWTX Edgewise Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.